A smarter steroid schedule might tame Chemotherapy's blood sugar spike

NCT ID NCT03505762

Ongoing Disease control Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether adjusting the dose of prednisone, a steroid in the R-CHOP chemotherapy regimen, can prevent high blood sugar (hyperglycemia) in adults with B-cell non-Hodgkin lymphoma. Participants are randomly assigned to either the standard prednisone dose or a tailored reduction based on their blood sugar levels. The goal is to see if a lower, personalized steroid dose can keep blood sugar in check without compromising lymphoma treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tailored prednisone reduction
What this could lead to: If effective, this approach could help manage blood sugar levels during chemotherapy, potentially reducing complications and improving treatment tolerability.
What could go wrong: This is a small phase II pilot, so results may not be definitive. Reducing prednisone could affect lymphoma control, and the approach may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.